After considering the feedback from consultation, the Appraisal Committee has prepared a final appraisal determination (FAD) on sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma and submitted it to the Institute.

Please refer to the letter below.

The FAD has been sent to the formal consultees for this appraisal who have 18 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5pm on Monday 2 March.

The guidance on first line use of sunitinib has been developed on the understanding that the currently available treatment for advanced and/or metastatic renal cell carcinoma is immunotherapy (namely interferon-alfa and interleukin-2). The Institute recognises that there are people who have had or who are currently receiving immunotherapy and wish to clarify the implications of the guidance for these people. Sunitinib can be considered as a treatment option for those people with advanced and/or metastatic RCC who are currently receiving immunotherapy or who have had immunotherapy before the release of our final recommendations to ensure they are not disadvantaged by our proposed guidance.